Diuretic effect and disposition of furosemide in cystic fibrosis
- PMID: 2050167
- DOI: 10.1007/BF00265840
Diuretic effect and disposition of furosemide in cystic fibrosis
Abstract
The pharmacodynamics and kinetics of single oral and intravenous doses of furosemide were studied in 9 patients (mean age 18.5 y) with cystic fibrosis. The diuretic effect of furosemide lasted for 6 h after oral administration and 2 h following intravenous injection of the drug. The patients with cystic fibrosis had a more pronounced diuretic response both to the oral and intravenous treatments than that reported in normals. Furosemide caused a marked decrease in urine pH for 5 h following the oral dose and between the 2nd and 3rd h after i.v. injection. The baseline nocturnal urine flow rate in 7 of the 9 patients given furosemide orally was increased by 30.6% compared to that reported in healthy subjects. The bioavailability of furosemide, its mean absorption rate and the mean plasma and urinary elimination half-lives both of the oral and the intravenous drug were similar to those reported in normal subjects. The patients with cystic fibrosis showed, however, about double normal mean total clearance after both the oral and i.v. treatments, and its renal clearance was almost half the plasma clearance. Nonrenal clearance was markedly increased in the patients, which agreed with a considerable decrease in the renal excretion of the drug. The mean apparent volume of distribution was also markedly increased compared to data in the literature. Oral furosemide resulted in a moderate increase in haematocrit and haemoglobin levels in 7 of 9 patients with cystic fibrosis and marked hypokalemia developed in 6 of the 9 patients 6 h after dosing. Pulmonary function tests performed at that time were changed in an inconsistent manner.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis.Clin Pharmacol Ther. 1988 Oct;44(4):436-41. doi: 10.1038/clpt.1988.177. Clin Pharmacol Ther. 1988. PMID: 3168395
-
Clinical pharmacology of furosemide in children: a supplement.Am J Ther. 2001 Jul-Aug;8(4):275-89. doi: 10.1097/00045391-200107000-00010. Am J Ther. 2001. PMID: 11441327 Review.
-
A study on furosemide disposition in man.J Pharmacobiodyn. 1987 Aug;10(8):370-6. doi: 10.1248/bpb1978.10.370. J Pharmacobiodyn. 1987. PMID: 3694431
-
Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.Arzneimittelforschung. 1988 Jan;38(1A):160-3. Arzneimittelforschung. 1988. PMID: 3370062 Clinical Trial.
-
Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.J Pharm Pharmacol. 1999 Mar;51(3):239-48. doi: 10.1211/0022357991772402. J Pharm Pharmacol. 1999. PMID: 10344623 Review.
Cited by
-
Diuretics in pediatrics : current knowledge and future prospects.Paediatr Drugs. 2006;8(4):245-64. doi: 10.2165/00148581-200608040-00004. Paediatr Drugs. 2006. PMID: 16898855 Review.
-
The efficiency concept in pharmacodynamics.Clin Pharmacokinet. 1999 May;36(5):375-89. doi: 10.2165/00003088-199936050-00005. Clin Pharmacokinet. 1999. PMID: 10384860 Review.
-
An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload.Clin Pharmacokinet. 2025 Jun;64(6):899-908. doi: 10.1007/s40262-025-01515-2. Epub 2025 May 13. Clin Pharmacokinet. 2025. PMID: 40360952 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical